Skip Navigation



Annals of Oncology Advance Access published online on November 9, 2005
Annals of Oncology, doi:10.1093/annonc/mdj068
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/297    most recent
mdj068v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kröger, K.
Right arrow Articles by Scheulen, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kröger, K.
Right arrow Articles by Scheulen, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received March 29, 2005
Revised September 6, 2005
Accepted October 7, 2005

original article

Risk factors for venous thromboembolic events in cancer patients

K. Kröger 1*, D. Weiland 2, C. Ose 2, N. Neumann 1, S. Weiss 1, C. Hirsch 1, K. Urbanski 1, S. Seeber 3, and M. E. Scheulen 3

1 Department of Angiology, University of Essen Medical School, Germany
2 Institute of Medical Informatics, Biometry and Epidemiology, University of Essen Medical School, Germany
3 Department of Internal Medicine (Cancer Research), University of Essen Medical School, Germany

* To whom correspondence should be addressed.
K. Kröger, E-mail: knut.kroeger{at}uni-essen.de


  Abstract

Background: Cancer patients of the Department of Internal Medicine (Cancer Research) of the Essen University Medical School (Tumor Clinics), Germany, were examined and questioned with the aim of identifying those who run a high risk of deep vein thrombosis (DVT).

Patients and methods: Between September 2002 and April 2003, cancer therapy and DVT risk factors of 507 cancer patients (53% males, 47% females, mean age 56 ± 12 years) were documented. During a mean follow-up of 8 ± 5 months, 60 patients (12%) suffered from new venous thromboembolic events (VTE): 28 at the lower limb, 25 at the upper limb and 13 pulmonary embolisms.

Results: The following factors were considered as predictive for an increased VTE risk: inpatient treatment (P < 0.0001), prior DVT in medical history (P = 0.0275), DVT in family (P = 0.0598), chemotherapy (P = 0.0080), fever (P = 0.0093) and CRP (P < 0.001). After combining factors in one variable (number of factors) the predicted VTE risk increased with the number of factors in both outpatients (OR 1.85, 95% CI 1.18-2.88, P = 0.0071) and inpatients (OR 2.34, 95% CI 1.63-3.36, P ≤ 0.0001). In the absence of all these factors the predicted VTE risk was 2.3%, increasing to 72% if all were present.

Conclusions: In cancer patients the risk of VTE steadily increases with the number of risk factors, and identification of patients at high risk is possible.

Keywords: deep vein thrombosis; risk assessment; cancer; chemotherapy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. A. Khorana and G. C. Connolly
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
J. Clin. Oncol., October 10, 2009; 27(29): 4839 - 4847.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Ay, R. Vormittag, D. Dunkler, R. Simanek, A.-L. Chiriac, J. Drach, P. Quehenberger, O. Wagner, C. Zielinski, and I. Pabinger
D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
J. Clin. Oncol., September 1, 2009; 27(25): 4124 - 4129.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. Cortes, C. Saura, and F. Atzori
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
JAMA, April 8, 2009; 301(14): 1434 - 1435.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
T. Sousou and A. A. Khorana
New Insights Into Cancer-Associated Thrombosis
Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 316 - 320.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. A. Khorana and G. H. Lyman
Incidence and Prevention of Cancer-associated Thrombosis
ASCO Educational Book, January 1, 2009; 2009(1): 321 - 325.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. A. Khorana, N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis
Development and validation of a predictive model for chemotherapy-associated thrombosis
Blood, May 15, 2008; 111(10): 4902 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman
The Risk of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al.
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
J. Clin. Oncol., December 1, 2007; 25(34): 5490 - 5505.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.